ATOS250117C5000
- 0.05
- 0.000.00%
Atossa Therapeutics Newsroom
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7
HC Wainwright & Co. Reiterates Buy on Atossa Therapeuticsto Buy
Atossa Therapeutics To Present Data Describing the Discovery of Compounds That May Be Synergistic With (Z)-Endoxifen And That Could Potentially Be Used in Combinations For The Treatment Of Breast Cancer. The Data Will Be Presented In A Poster At The...
Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density
Express News | Atossa Therapeutics: 2 Mg Dose Was Associated With Higher Rates of Hot Flashes, Night Sweats and Vaginal Discharge
Express News | Atossa Therapeutics - 1 Mg Dose Reduced Mbd by 17.3 Percentage Points, 2 Mg Dose by 23.5 Vs Minimal Change in Placebo Group of 0.27
Express News | Atossa Therapeutics Inc - 1 Mg Dose (Z)-Endoxifen Shows Potential as Preventative Breast Cancer Therapy
Express News | Atossa Therapeutics Announces Full Results From Phase 2 Karisma-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data From Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
Atossa Therapeutics Is Maintained at Buy by Ascendiant Capital
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Atossa Therapeutics To Present Five Abstracts For Data Regarding (Z)-Endoxifen At 2024 San Antonio Breast Cancer Symposium
Express News | Atossa Therapeutics- Got Into Open Market Sale Agreement, May Offer & Sell Shares of Our Common Stock of up to $100 Mln From Time to Time - SEC Filing
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Raises Target Price to $7
Promising Developments in Atossa Therapeutics: Advancing Endoxifen Treatments
Atossa Therapeutics | 8-K: Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Atossa Therapeutics | 10-Q: Q3 2024 Earnings Report
Atossa Therapeutics GAAP EPS of -$0.06 In-line
Express News | Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update